TY - JOUR
T1 - Chemotherapy of human African trypanosomiasis
T2 - current and future prospects
AU - Fairlamb, Alan H.
N1 - Funding Information:
A.H.F. thanks the Wellcome Trust for support under the Principal Research Fellowship Scheme.
PY - 2003/11/1
Y1 - 2003/11/1
N2 - Three of the four currently approved drugs for the treatment of African trypanosomiasis (sleeping sickness) were developed over 50 years ago. All of the current therapies are unsatisfactory for various reasons, including unacceptable toxicity, poor efficacy, undesirable route of administration, and drug resistance. The possible modes of action of these drugs are briefly reviewed, as are the possible mechanisms of resistance. The intermediate and long-term prospects for the development of safer, effective drugs are discussed.
AB - Three of the four currently approved drugs for the treatment of African trypanosomiasis (sleeping sickness) were developed over 50 years ago. All of the current therapies are unsatisfactory for various reasons, including unacceptable toxicity, poor efficacy, undesirable route of administration, and drug resistance. The possible modes of action of these drugs are briefly reviewed, as are the possible mechanisms of resistance. The intermediate and long-term prospects for the development of safer, effective drugs are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0142258170&partnerID=8YFLogxK
U2 - 10.1016/j.pt.2003.09.002
DO - 10.1016/j.pt.2003.09.002
M3 - Review article
C2 - 14580959
AN - SCOPUS:0142258170
SN - 1471-4922
VL - 19
SP - 488
EP - 494
JO - Trends in Parasitology
JF - Trends in Parasitology
IS - 11
ER -
